French Startup Gleamer Raises $29.4M for AI-Powered Medical Imaging

What You Should Know: 

• Gleamer, a Paris, France-based European manufacturer in AI-powered solutions for medical imaging raises €27M ($29.4M USD) in Series B funding led by Supernova Invest, co-led by Heal Capital and backed by Gleamer’s long-term partners XAnge, Elaia, Bpifrance via the funds Digital Venture and F3A from France 2030, MACSF, Crista Galli Ventures, and UI Investissement, as well as several European radiologists. 
• Founded in 2017, Gleamer’s suite of AI-powered solutions supports radiologists and clinicians in their diagnoses, thereby improving reliability and reducing the time taken to read and process examinations.

Medical Grade AI for Radiology

Gleamer’s clinical AI diagnostic solutions offering includes: 

• BoneView Measurements: automates daily measurements and simplifies interpretation with an easy-to-read display.
• BoneView Bone Age: algorithm automates bone age assessment using the Greulich & Pyle atlas method, saving valuable time while ensuring precision.
• BoneView FDA: provides radiologists and ED doctors with an instant and automatic 2nd reading of trauma X-Rays fully integrated into the reading workflow.
• ChestView: provides radiologists and clinicians with an instant and automatic 2nd reading of Chest X-Rays fully integrated in the reading workflow.

International Expansion 

Gleamer will cover 70% of radiologists’ daily (or “routine”) needs. The company aims to accelerate its international expansion, particularly in Europe and in the United States where the sales teams will be strengthened. In addition, Gleamer will extend existing strategic partnerships, while signing new large-scale partnerships with local and global players in the medical imaging field, to make Gleamer’s solutions accessible to as many people as possible.

Now serving over 6,500 users in 650 institutions, spanning 24 countries, its solutions process more than a million medical examinations each month. This new funding gives Gleamer the resources to achieve its strategic roadmap, and to deploy disruptive technological solutions at scale to meet the expectations of medical staff worldwide.

ai
medical
fda